Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363605 · ClinicalTrials.gov registry record · Phase 1
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
A Phase 1 study, sponsored by Fusion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05363605: Clinical Trial Phase 1 study, sponsored by Fusion Pharmaceuticals.
NCT05363605 is a Phase 1 study that was terminated before completion, run by Fusion Pharmaceuticals. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05363605, a Phase 1 study, was terminated before completion, sponsored by Fusion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This first-in-human study evaluates safety, tolerability and distribution of \[225Ac\] FPI-1966, \[111In\]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
Interventions
- DRUG [225Ac]-FPI-1966
- DRUG [111In]-FPI-1967
- BIOLOGICAL vofatamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 1 |
Why NCT05363605 stopped before completion
NCT05363605 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which [225Ac]-FPI-1966 is the first listed.
NCT05363605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05363605 about?
NCT05363605 is a clinical study titled "A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours". This first-in-human study evaluates safety, tolerability and distribution of \[225Ac\] FPI-1966, \[111In\]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
What is the current status of trial NCT05363605?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-04-20. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT05363605?
The interventions under investigation include: [225Ac]-FPI-1966 (DRUG), [111In]-FPI-1967 (DRUG), vofatamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05363605?
This trial is sponsored by Fusion Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05363605's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI